Chemical Name: (3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide
Biological ActivityGSK 2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDPK1) inhibitor (IC50 ~ 10 nM). Exhibits no effect on other kinases including Aurora, ROCK, p38 MAPK and PI 3-K. Suppresses T-loop phosphorylation and subsequent activation of PDK1 substrates S6K1, SGK and RSK in vitro; exhibits limited inhibitory effect on Akt activation. Delays melanomagenesis and metastasis in BrafV600E::Pten(-/-) mice.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of GSK 2334470 is reviewed on the chemical probes website.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov et al.
Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten(-/-) melanoma.
Scortegagna et al.
Citations for GSK 2334470
The citations listed below are publications that use Tocris products. Selected citations for GSK 2334470 include:
5 Citations: Showing 1 - 5
The PI3K and MAPK/p38 pathways control stress granule assembly in a hierarchical manner.
Authors: Heberle Et al.
Life Sci Alliance 2019;2
The 3-Phosphoinositide-Dependent Protein Kinase 1 Inhibits Rod Photoreceptor Development.
Authors: Xing Et al.
Front Cell Dev Biol 2018;6:134
Retinoic acid regulates Kit translation during spermatogonial differentiation in the mouse.
Authors: Busada Et al.
PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.
Authors: Qi Et al.
Cancer Cell Int 2015;15:91
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.
Authors: Al-Ejeh Et al.
PLoS One 2014;5:3145
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for GSK 2334470
There are currently no reviews for this product. Be the first to review GSK 2334470 and earn rewards!
Have you used GSK 2334470?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image